Ampicillin Plus Ceftriaxone Is as Effective as Ampicillin Plus Gentamicin for Treating Enterococcus faecalis Infective Endocarditis
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aim of this study was to compare the effectiveness of the ampicillin plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) combinations for treating Enterococcus faecalis infective endocarditis (EFIE). METHODS: An observational, nonrandomized, comparative multicenter cohort study was conducted at 17 Spanish and 1 Italian hospitals. Consecutive adult patients diagnosed of EFIE were included. Outcome measurements were death during treatment and at 3 months of follow-up, adverse events requiring treatment withdrawal, treatment failure requiring a change of antimicrobials, and relapse. RESULTS: A larger percentage of AC-treated patients (n = 159) had previous chronic renal failure than AG-treated patients (n = 87) (33% vs 16%, P = .004), and AC patients had a higher incidence of cancer (18% vs 7%, P = .015), transplantation (6% vs 0%, P = .040), and healthcare-acquired infection (59% vs 40%, P = .006). Between AC and AG-treated EFIE patients, there were no differences in mortality while on antimicrobial treatment (22% vs 21%, P = .81) or at 3-month follow-up (8% vs 7%, P = .72), in treatment failure requiring a change in antimicrobials (1% vs 2%, P = .54), or in relapses (3% vs 4%, P = .67). However, interruption of antibiotic treatment due to adverse events was much more frequent in AG-treated patients than in those receiving AC (25% vs 1%, P < .001), mainly due to new renal failure (≥25% increase in baseline creatinine concentration; 23% vs 0%, P < .001). CONCLUSIONS: AC appears as effective as AG for treating EFIE patients and can be used with virtually no risk of renal failure and regardless of the high-level aminoglycoside resistance status of E. faecalis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the study by Fernández-Hidalgo et al, 191 26% of the 272 patients had high-level aminoglycoside-resistant strains of E faecalis.”
In the citing paper
“Sixth, in the larger study, there were no significant differences between ampicillin-ceftriaxone and ampicillin-gentamicin in the need for surgery, complications (except for fewer cases of renal failure in the ampicillin-ceftriaxone group), relapse, or mortality.”
In the citing paper
“Second, high-level aminoglycoside-resistant E faecalis IE treated with ampicillin-ceftriaxone therapy was present in 50% of the patients in the smaller study and 33% of patients in the larger study.”
In the citing paper
“Fourth, in the larger study, the median age was 70 years in both treatment groups; however, patients in the ampicillin-ceftriaxone group were generally sicker and had more comorbid conditions (eg, chronic renal failure [P=0.004],neoplasm [P=0.015], and nosocomial acquisition of infection [P=0.006]).”
In the citing paper
“First, these are the largest series of E faecalis IE reported to date, 43 patients in 1 study 190 and 272 in the other study.191”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027 · cited 1×
“Definitions IE was defined as definite or possible according to the modified Duke criteria [10].”
MethodMurdoch, D. R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.603 · Cited by 2,362
Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer, Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., de Jesus Antunes, M., Thilen, U., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp285 · Cited by 2,014
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Preeminence of Staphylococcus aureus in Infective Endocarditis: A 1-Year Population-Based Survey
Selton-Suty, C., Célard, M., Le Moing, V., Doco-Lecompte, T., Chirouze, C., Iung, B., Strady, C., Revest, M., Vandenesch, F., Bouvet, A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis199 · Cited by 710
Intravascular catheter-related infections: advances in diagnosis, prevention, and management
Raad, I., Hanna, H., & Maki, D. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70235-9 · Cited by 525 · cited 1×
“Healthcare-associated IE [11] and catheter-related bacteremia [12] have been defined elsewhere.”
BackgroundContemporary Epidemiology and Prognosis of Health Care–Associated Infective Endocarditis
Fernández‐Hidalgo, N., Almirante, B., Tornos, P., Pigrau, C., Sambola, A., Igual, A., & Pahissa, A. (2008) · Clinical Infectious Diseases · doi:10.1086/592576 · Cited by 217
Self-citationGavaldà, J., Len, O., Miró, J. M., Muñoz, P., Montejo, M., Alarcón, A., de la Torre-Cisneros, J., Peña, C., Martínez-Lacasa, X., Sarria, C., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00008 · Cited by 202 · cited 3×
“Since the publication of an observational, nonrandomized, multicenter clinical trial in 2007 [9], the ampicillin plus ceftriaxone (AC) combination has been recognized as a viable alternative for treating E.”
BackgroundSelf-citationMcDonald, J. R., Olaison, L., Anderson, D. J., Hoen, B., Miro, J. M., Eykyn, S., Abrutyn, E., Fowler, V. G., Habib, G., Selton-Suty, C., et al. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.020 · Cited by 170
Cited by
Items 101–200 of 346
Escolà‐Vergé, L., Fernández‐Hidalgo, N., Rodríguez-Pardo, D., Pigrau, C., González‐López, J. J., Bartolomé, R. M., & Almirante, B. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.10.003 · Cited by 25
Self-citationRamos, A., Pericàs, J. M., Fernández‐Cruz, A., Muñóz, P., Valerio, M., Kestler, M., Montejo, M., Fariñas, M. C., Sousa, D., Domínguez, F., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237011 · Cited by 24
Self-citationShah, N. H., Shutt, K. A., & Doi, Y. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab102 · Cited by 24
“The largest of these, a 2013 multicenter observational study performed by Fernández-Hidalgo and colleagues in Europe, reported no differences in mortality, treatment failure, or relapse between EIE patients treated with AC or ampicillin-gentamicin (AG).”
ResultInfective endocarditis in Ethiopian children: a hospital based review of cases in Addis Ababa
Moges, T., Gedlu, E., Isaakidis, P., Kumar, A. M. V., Den, R. V., Khogali, M. A., Mekasha, A., & Hinderaker, S. G. (2015) · Pan African Medical Journal · doi:10.11604/pamj.2015.20.75.4696 · Cited by 24
“This is in contrast to most reports even from similar settings from other low or middle income countries [19].”
BackgroundResultCombination antibiotic therapy for the treatment of infective endocarditis due to enterococci
Leone, S., Noviello, S., & Esposito, S. (2015) · Infection · doi:10.1007/s15010-015-0836-0 · Cited by 22
“However, the rate of adverse events requiring treatment withdrawal, mainly due to kidney failure, was significantly higher in the aminoglycosidebased regimen compared to the experimental regimen [31].”
ResultLadjouzi, R., Bizzini, A., van Schaik, W., Zhang, X., Rincé, A., Benachour, A., & Hartke, A. (2015) · Journal of Bacteriology · doi:10.1128/jb.00389-15 · Cited by 22
Should High-dose Daptomycin be an Alternative Treatment Regimen for Enterococcal Endocarditis?
Peghin, M., Russo, A., Givone, F., Ingani, M., Graziano, E., & Bassetti, M. (2019) · Infectious Diseases and Therapy · doi:10.1007/s40121-019-00261-w · Cited by 22
Hidalgo, L. H., Lomas-Cabezas, J. M., López-Cortés, L. E., Márquez, R. L., López-Cortés, L. F., Martínez‐Marcos, F. J., Lima, J. D. L. T., Plata, A., Hidalgo-Tenorio, C., García-López, M. V., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010007 · Cited by 22
“Ampicillin 2 g every 4 h plus ceftriaxone 2 g every 12 h combined therapy (AC12) is the preferred inpatient regimen, since it shows a lower rate of adverse effects than the regimens based on the combination of ampicillin plus gentamycin [7].”
BackgroundSelf-citationIn vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium
Lorenzo, M. P., Kidd, J. M., Jenkins, S. G., Nicolau, D. P., & Housman, S. T. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz173 · Cited by 21
Peiffer‐Smadja, N., Guillotel, E., Luque-Paz, D., Maataoui, N., Lescure, F.-X., & Cattoir, V. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz388 · Cited by 21
Cattaneo, C., Rieg, S., Schwarzer, G., Müller, M. C., Blümel, B., & Kern, W. V. (2021) · Infection · doi:10.1007/s15010-021-01717-3 · Cited by 21
Mirna, M., Topf, A., Schmutzler, L., Hoppe, U. C., & Lichtenauer, M. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01971-3 · Cited by 21
“Data on the primary outcome of in-hospital mortality were available from all 4 studies, whereas data on the secondary outcome of 3-month mortality were available from 3 studies only [12, 19, 20].”
BackgroundMethodResultLeft-sided infective endocarditis in patients with liver cirrhosis
Ruiz‐Morales, J., Georgieva, R. I., Fernández‐Hidalgo, N., García-Cabrera, E., Miró, J. M., Muñóz, P., Almirante, B., Plata, A., Ramallo, V. J. G., Gálvez-Acebal, J., et al. (2015) · Journal of Infection · doi:10.1016/j.jinf.2015.09.005 · Cited by 20
Self-citationPeterson, S. C., Lau, T. T. Y., & Ensom, M. H. H. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017692357 · Cited by 20
“67) between the ampicillin plus ceftriaxone and the ampicillin plus gentamicin groups, respectively.(17) Discontinuation of therapy as a result of an adverse event was more common in the ampicillin and gentamicin group (25% vs 1%, P < 0.”
BackgroundMethodResultInfluentialAnalysis of the 2015 American and European guidelines for the management of infective endocarditis
Tattevin, P., & Mainardi, J. (2016) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2016.05.008 · Cited by 21
Giuliano, S., Angelini, J., D’Elia, D., Geminiani, M., Barison, R. D., Giacinta, A., Sartor, A., Campanile, F., Curcio, F., Cotta, M. O., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12050879 · Cited by 19
Therapeutic Options for Infections Due to vanB Genotype Vancomycin-Resistant Enterococci
Riccardi, N., Monticelli, J., Antonello, R. M., Lallo, G. D., Frezza, D., Luzzati, R., & Bella, S. D. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0171 · Cited by 19
Briggs, S. E., Broom, M., Duffy, E., Everts, R. J., Everts, G., Lowe, B. S., McBride, S., & Bhally, H. S. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab132 · Cited by 19
Liao, C., Huang, Y., Tsai, H.-Y., & Hsueh, P. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.03.011 · Cited by 19
Emonet, S., Wuillemin, T., Harbarth, S., Wassilew, N., Çıkırıkçıoğlu, M., Schrenzel, J., Lagier, J., Raoult, D., & van Delden, C. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.11.003 · Cited by 19
“This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). reported by Fernandez-Hidalgo.1 The patient was discharged on double strength TMP-SMX, which had been used since the first hospitalization.”
BackgroundInfluentialCusumano, J. A., Khan, R., Shah, Z., Philogene, C., Harrichand, A., & Huang, V. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00621-22 · Cited by 18
Clinical characteristics, microbiology, and outcomes of infective endocarditis in Qatar
Zaqout, A., Mohammed, S., Thapur, M., Soub, H. A., Almaslamani, M., Al‐Khal, A., & Omrani, A. S. (2020) · Qatar medical journal · doi:10.5339/qmj.2020.24 · Cited by 17
“Examples include daptomycin for methicillinresistant S. aureus (MRSA) and vancomycin-resistant Enterococcus species15 and ampicillin/ceftriaxone combination for the treatment of E. faecalis IE.16 The initial promise of glycopeptide/b-lactam combinations for MRSA bloodstream infections was not supported by the results…”
ResultInfluentialSuleyman, G., & Zervos, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1127349 · Cited by 18
“Gentamicin levels were not monitored consistently, and 64% of subjects did not complete the 6 weeks of AG for various reasons.[23] Interestingly, AC has been used successfully in patients with various”
MethodTherapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections
Turner, A. M., Kinsella, P. M., Miller, W. R., Carter, G. P., Tran, T. T., Howden, B. P., & Arias, C. A. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01060-24 · Cited by 17
“This “dual” PBP effect is bactericidal and appears to be as efficacious as the combination of ampicillin plus gentamicin (98).”
Endocarditis Caused by Resistant Enterococcus: An Overview
Reyes, K., & Zervos, M. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0348-y · Cited by 16
The combination of ampicillin plus ceftaroline is synergistic againstEnterococcus faecalis
Werth, B. J., & Abbott, A. N. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv125 · Cited by 16
Faraji, R., Behjati‐Ardakani, M., Faraji, N., Moshtaghioun, S. M., Kalantar, S. M., Pedarzadeh, A., Zandi, H., Sarebanhassanabadi, M., Ahmadi, N., & Firoozabadi, A. D. (2018) · Cardiology Research · doi:10.14740/cr687w · Cited by 16
“According to the reports by some studies, microorganisms most frequently involved in the etiology of IE are from the Staphylococcus, Streptococcus, and Enterococcus genus in the developed countries, respectively [13, 14].”
BackgroundWerth, B. J., & Shireman, L. M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02235-16 · Cited by 16
“tion of ampicillin plus gentamicin (4).”
Cusumano, J. A., Daffinee, K. E., Ugalde‐Silva, P., Peti, W., Arthur, M., Desbonnet, C. R., Rice, L. B., LaPlante, K. L., & Garcia-Solache, M. A. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00871-22 · Cited by 15
“coside resistance (8, 9) and concerns of aminoglycoside toxicity (10, 11) have”
BackgroundWestbrook, K. J., Chilambi, G. S., Stellfox, M. E., Nordstrom, H. R., Li, Y., Iovleva, A., Shah, N. H., Jones, C. E., Kline, E. G., Squires, K. M., et al. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae032 · Cited by 15
Cusumano, J. A., Kalogeropoulos, A. P., Provost, M. L., Gallo, N. R., Levine, S. M., Inzana, T. J., & Papamanoli, A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00168-23 · Cited by 15
Contemporary Drug Treatment of Infective Endocarditis
Sabe, M., Shrestha, N. K. M., & Menon, V. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0015-6 · Cited by 15
My paper 10 years later: infective endocarditis in the intensive care unit
Wolff, M., Mourvillier, B., Sonneville, R., & Timsit, J. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3490-6 · Cited by 15
Rehman, M., Hasan, K. A., Bin-Asif, H., Akram, S., Zahid, S., Mirani, Z. A., & Ali, S. A. (2021) · Environmental Challenges · doi:10.1016/j.envc.2021.100094 · Cited by 15
Omadacycline in treating community-based infections: a review and expert perspective
Sakoulas, G., Nowak, M., & Geriak, M. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2174100 · Cited by 15
Falcone, M., Tiseo, G., Dentali, F., Foglia, E., Campanini, M., Menichetti, F., & Mazzone, A. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.02.014 · Cited by 15
“Since delay in delivery of appropriate antibiotic therapy is associated with higher mortality [18], receipt of an early communication from the laboratory could be essential in such cases.”
BackgroundSelf-citationHidalgo, L. H., de Alarcón, A., López-Cortés, L. E., Márquez, R. L., López-Cortés, L. F., Gutiérrez‐Valencia, A., & Gil-Navarro, M. V. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02099-20 · Cited by 15
“The employed regimen consisted of 2 g of ceftriaxone given every 12 h plus 2 g of ampicillin given every 4 h and the results showed no differences in effectiveness compared with ampicillin plus gentamicin combination (AG), whereas AC was found less nephrotoxic (9).”
BackgroundMethodLeggett, J. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00025-4 · Cited by 15
Leggett, J. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00143-x · Cited by 15
Lewis, J. S., & Bush, K. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch68 · Cited by 15
Gatti, M., Tedeschi, S., Trapani, F., Ramirez, S., Mancini, R., Giannella, M., Viale, P., & Pea, F. (2022) · Antibiotics · doi:10.3390/antibiotics11081037 · Cited by 14
Arribas, D. G., Olmos, C., Vivas, D., & Vilacosta, I. (2017) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2017.09.004 · Cited by 14
Self-citationHidalgo-Tenorio, C., Sadyrbaeva-Dolgova, S., Aparicio‐Minguijón, E., de Alarcón, A., Plata, A., Marcos, F. J. M., Álvarez-Álvarez, B., Loeches, B., Varisco, B., Estévez, A., et al. (2025) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2025.03.001 · Cited by 13
Self-citationFakhriRavari, A., Simiyu, B., Morrisette, T., Dayo, Y., & Abdul‐Mutakabbir, J. C. (2022) · Drugs in Context · doi:10.7573/dic.2021-8-9 · Cited by 13
Tholany, J., Kobayashi, T., Marra, A. R., Schweizer, M. L., Samuelson, R. J., & Suzuki, H. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac200 · Cited by 13
“mortality of 15% and a 1-year mortality rate of 35% [11], while another study found a relapse rate of about 5% [12].”
BackgroundDual beta-lactam treatment: Pros and cons
Guerra, D., Vidal, P., Paccoud, O., Maillard, A., Cachera, L., Junot, H., Gauzit, R., Zahar, J., Abreu, M. A., & Bleibtreu, A. (2022) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000189 · Cited by 13
Linee guida ESC 2023 per il trattamento dell’endocardite
Marsan, N. A., de Waha, S., Bonaros, N. E., Brida, M., Burri, H., Caselli, S., Doenst, T., Éderhy, S., Erba, P. A., Foldager, D., et al. (2023) · Giornale Ialiano di Cardiologia · doi:10.1714/4144.41413 · Cited by 13
Béraud, G., Pulcini, C., Paño‐Pardo, J. R., Hoen, B., Beovič, B., & Nathwani, D. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.10.013 · Cited by 13
“faecalis IE, the ampicillin and ceftriaxone combination showed efficiency similar to that of the ampicillin and gentamicin association but with less renal failure [26].”
ResultKarimi, F., Samarghandi, M. R., Shokoohi, R., Godini, K., & Arabestani, M. R. (2016) · Avicenna Journal of Environmental Health Engineering · doi:10.5812/ajehe.8623 · Cited by 13
“Based on international guidelines (CLSI), a combination of the antibiotic of Ampicillin and an aminoglycoside antibiotic (including Gentamicin, Streptomycin, and Kanamycin) is used for treatment of Enterococcal infections (29).”
BackgroundYavuz, S. Ş., Akar, A., Aydoğdu, S., Berzeg-Deniz, D., Demir, H., Hazırolan, T., Özatık, M. A., Özer, N., Sarğın, M., Topçuoğlu, N., et al. (2020) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2020.01954 · Cited by 13
Significant publications on infectious diseases pharmacotherapy in 2013
Hunter, A. S., Guervil, D. J., Perez, K. K., Schilling, A. N., Verheyden, C. N., Vuong, N. N., & Xu, R. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140148 · Cited by 13
Fernández-Rubio, B., Hidalgo, L. H., Márquez, R. L., de Alarcón, A., López-Cortés, L. E., Luque, S., Gutiérrez-Urbón, J. M., Fernández-Polo, A., Gil-Navarro, M. V., & Gutiérrez‐Valencia, A. (2023) · Antibiotics · doi:10.3390/antibiotics12030432 · Cited by 12
Jimenez-Toro, I. E., Rodríguez, C. A., Zuluaga, A. F., Otalvaro, J. D., & Vesga, Ó. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243365 · Cited by 12
Okumura, N., Watanabe, T., Teranishi, S., Suzuki, D., Hashimoto, T., Takahashi, K., & Hara, T. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06160-1 · Cited by 12
Streptococcal and enterococcal endocarditis: time for individualized antibiotherapy?
Flateau, C., Riazi, A., Cassard, B., Camus, M., & Diamantis, S. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab333 · Cited by 12
Aminoglycoside antibiotics: Trying to find a place in this world
Deja, E. N. (2024) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2024.03.002 · Cited by 11
Sánchez, M. Á. G., Urkola, X. K., Santiago, E. B., Muñóz, P., Moreno, E. V., Fariñas, M. C., Cobo, R. T., Pericàs, J. M., González, A. D. A., Regueiro, D. S., et al. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.03.009 · Cited by 11
In search of novel protein drug targets for treatment of Enterococcus faecalis infections
Singh, H., Das, S., Yadav, J., Srivastava, V. K., Jyoti, A., & Kaushik, S. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13582 · Cited by 11
“Treatment of Ef has usually involved the use of β‐lactams, aminoglycosides, glycopeptides, vancomycin, and ampicillin (Fernández‐Hidalgo et al., 2013).”
BackgroundEndocarditis in kidney transplant recipients: a systematic review
Ιωάννου, Π., Alexakis, K., & Kofteridis, D. P. (2020) · Journal of Chemotherapy · doi:10.1080/1120009x.2020.1861512 · Cited by 11
Tholany, J., Suzuki, H., Livorsi, D. J., Perencevich, E. N., & Goto, M. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.03.009 · Cited by 11
Akers, S. M., Kinney, K., Butcher, M. I., & Moïse, A. A. (2020) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-25.6.547 · Cited by 11
Enterococcus hirae Bacteremia in an Infant: Case Report and Review of the Literature
Brayer, S. W., Linn, A., Holt, S. C., Ellery, K., Mitchell, S. L., & Williams, J. J. (2019) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piz028 · Cited by 11
Combination Antimicrobial Therapy for Enterococcus faecalis Infective Endocarditis
Koehler, P. A., Jung, N., Cornely, O. A., Rybniker, J., & Fätkenheuer, G. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz054 · Cited by 11
Haliga, R. E., Șorodoc, V., Morarasu, B. C., Coman, A. E., Ceasovschih, A., Sîrbu, O., Lionte, C., Bologa, C., Stoica, A. M., Constantin, M., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020300 · Cited by 10
Enterococcal endocarditis management and relapses
Garofoli, N., Joly, V., Pluart, D. L., Hobson, C. A., Beaumont, A., Lariven, S., Grall, N., Para, M., Yazdanpanah, Y., Lescure, F.-X., et al. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae033 · Cited by 10
Prosty, C. J., Sorin, M., Katergi, K., Khalaf, R., Fogarty, C., Turenne, M., Lee, T. C., & McDonald, E. G. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae379 · Cited by 10
A narrative review of the interpretation of guidelines for the treatment of infective endocarditis
Benedetto, U., Singh, S., Spadaccio, C., Moon, M. R., & Nappi, F. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3739 · Cited by 10
“In these reports it was shown that ampicillin/ceftriaxone was just as effective with reduced levels of nephrotoxicity (39,40).”
BackgroundEndocarditis in Liver Transplant Recipients: A Systematic Review
Ιωάννου, Π., Alexakis, K., & Kofteridis, D. P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122660 · Cited by 10
“Additional information was kindly provided by the corresponding authors of two studies [40,48].”
BackgroundColella, A., Greco, G., Cordisco, M., Tinelli, A., & Paradies, P. (2023) · Veterinary Record Case Reports · doi:10.1002/vrc2.724 · Cited by 9
New advances in management and treatment of cardiac implantable electronic devices infections
Russo, A., Serraino, R., Serapide, F., Trecarichi, E. M., & Torti, C. (2023) · Infection · doi:10.1007/s15010-023-02130-8 · Cited by 9
Giuliano, S., Angelini, J., Campanile, F., Conti, P., Flammini, S., Pagotto, A., Sbrana, F., Martini, L., D’Elia, D., Abdul-Aziz, M. H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-87512-8 · Cited by 9
Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery
Giacobbe, D. R., Corcione, S., Salsano, A., Puente, F. D., Pinna, S. M., Rosa, F. G. D., Mikulska, M., Santini, F., & Viscoli, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1574753 · Cited by 9
Harada, S., Shibue, Y., Aoki, K., Ishii, Y., & Tateda, K. (2020) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2019.416 · Cited by 9
Aetiology of renal failure in patients with infective endocarditis. The role of antibiotics
Sánchez, M. Á. G., Urkola, X. K., Santiago, E. B., García, P. M., Moreno, E. V., Fariñas, M. C., Cobo, R. T., Pericàs, J. M., González, A. D. A., Regueiro, D. S., et al. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.09.006 · Cited by 9
Freeman, L., Milkovits, A. E., McDaniel, L. F., & Everson, N. A. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106522 · Cited by 9
ENTEROCOCCUS RESISTENTE A VANCOMICINA (VRE): PERFIL GERAL
Santos, M. A. D., Paiva, I. C. D., & Andrade, E. G. D. S. A. E. G. D. S. (2021) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · doi:10.5281/zenodo.4613827 · Cited by 9
Antimicrobial Shortages: Another Hurdle for Clinicians
Valiquette, L., & Laupland, K. B. (2015) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2015/789369 · Cited by 9
Addressing the Menace of Enterococcal Endocarditis
Bashore, T. M., & Turner, N. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.009 · Cited by 9
Saman, R., Primus, C., West, R., Woldman, S., & Sandoe, J. A. T. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10451-2 · Cited by 8
Paz, D. L., Cuervo, G., Miró, J. M., & Tattevin, P. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.02.023 · Cited by 8
Broad-range PCR for early diagnosis of nosocomial Enterococcus gallinarum meningitis
Su, P. P., Miller, S. A., Rutishauser, R. L., & Babik, J. M. (2016) · Scandinavian Journal of Infectious Diseases · doi:10.3109/23744235.2016.1160422 · Cited by 8
“Drawing on data from treating Enterococcal endocarditis,[7,8] antibiotics were narrowed to ampicillin (2 g IV every 4 h) and ceftriaxone (2 g IV every 12 h) and he was treated for a 4-week course.”
MethodHow to manage patients in whom malignancy and infective endocarditis are associated: a review
Mistiaen, W. P., & Gebruers, N. (2019) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2019.1698762 · Cited by 7
“an important microbial agent in IE [8,10,11], but this is less,”
BackgroundGeismann, F., Handschuh, S., Malfertheiner, M. V., Salzberger, B., Bauernfeind, S., Hitzenbichler, F., Simon, M., Caplunik-Pratsch, A., Schneider‐Brachert, W., Wiest, C., et al. (2023) · Infection · doi:10.1007/s15010-023-02045-4 · Cited by 7
Aktuelle Therapie der Endokarditis: Neuerungen und Kontroversen
Hitzenbichler, F., Olic, J.-J., Hanses, F., Salzberger, B., Fischer, M., & Baessler, A. (2019) · Der Internist · doi:10.1007/s00108-019-00664-4 · Cited by 7
Jimenez-Toro, I. E., Rodríguez, C. A., & Zuluaga, A. F. (2019) · Revista chilena de infectología · doi:10.4067/s0716-10182019000500556 · Cited by 7
Castro-Lainez, M. T., Sierra‐Hoffman, M., Valladares, V., Tillman, T., Iznaloa-Esquivel, O. A., Howell, A. C., Fader, R., Winn, R. E., & Jinadatha, C. (2018) · IDCases · doi:10.1016/j.idcr.2018.e00460 · Cited by 7
“Multiple combinations have been advocated for enterococcal endocarditis including ampicillin and gentamicin, most recently ceftriaxone plus ampicillin [8], Ampicillin plus daptomycin has also been proven successful in a small cohort of 5 patients in which all had abnormal renal function [9].”
BackgroundEndocardite infecciosa: o que mudou na última década?
Salgado, Â. A., Lamas, C. D. C., & Bóia, M. N. (2013) · Revista Hospital Universitário Pedro Ernesto · doi:10.12957/rhupe.2013.7088 · Cited by 7
Funk, O. G., Khan, R., Shah, Z., & Cusumano, J. A. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02718-24 · Cited by 6
Infective Endocarditis: New Challenges in a Classic Disease
Cuervo, G., Meneses, M. H., Falces, C., Quintana, E., Vidal, B., Marco, F., Perissinotti, A., Carratalà, J., Miró, J. M., & The Hospital Clinic and the Hospital of Bellvitge Endocarditis Team Investigators (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1742482 · Cited by 6
Adema, J. L., Ahiskali, A., Fida, M., Hornback, K. M., Stevens, R. W., & Rivera, C. G. (2023) · Pathogens · doi:10.3390/pathogens12050703 · Cited by 6
“There was an increase in acute renal failure with aminoglycoside-containing regimens (46% vs. 33%, p = 0.51) and an increased rate of discontinuation due to renal failure (23% vs. 0%, p 0.001) [69].”
BackgroundInfluentialKarvouniaris, M., Aidoni, Z., Gkeka, E., Primikyri, S. N., Pagioulas, K., & Argiriadou, E. (2024) · Pathogens · doi:10.3390/pathogens14010003 · Cited by 6
Marıno, A., Munafò, A., Zagami, A., Ceccarelli, M., Campanella, E., Cosentino, F., Moscatt, V., Cantarella, G., Mauro, R. D., Bernardini, R., et al. (2022) · IDCases · doi:10.1016/j.idcr.2022.e01462 · Cited by 6
“Despite limitations given by retrospective data collection, the lack of a random assignment and the liberal and misleading definition of acute renal failure, with the interruption of aminoglycoside therapy left to the physicians’ choice, this study provided useful clinical data to support the use of A+C regimen for th…”
MethodInfluentialCusumano, J. A., Daffinee, K. E., Piehl, E. C., Garcia-Solache, M. A., Desbonnet, C. R., Rice, L. B., & LaPlante, K. L. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00426-22 · Cited by 6
Postpartum infective endocarditis with Enterococcus faecalis in Japan: a case report
Tamura, M., Shoji, M., Fujita, K. I., Nakamura, S., Takahashi, Y., Suzuki, Y., Asakura, M., Kimizuka, S., Sasaki, M., & Sugawara, K. (2017) · Journal of Medical Case Reports · doi:10.1186/s13256-017-1494-x · Cited by 6
“, 26% of 272 patients were infected by high-level aminoglycoside-resistant strains [19].”
BackgroundEndocarditis infecciosa neonatal: diagnóstico y tratamiento
Benítez, P. J. C., Morán, R. J. G., Hidalgo-Vázquez, M. M., López-Enríquez, C. D. C., Martínez-Hernández, A., Pedro, R. B.-S., & Iglesias-Leboreiro, J. (2019) · Revista Mexicana de Pediatría · doi:10.35366/sp195h · Cited by 6
Singh, K. V., Arias, C. A., & Murray, B. E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02303-19 · Cited by 6
Walsh, M. J., & Shetty, A. K. (2018) · Elsevier eBooks · doi:10.1016/b978-1-4557-0760-7.00070-x · Cited by 6
Philip, M., Gravier-Dumonceau, R., Citro, R., Cosyns, B., Donal, E., Erba, P. A., Gouriet, F., Iung, B., Kong, W. K. F., Lancellotti, P., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf145 · Cited by 5
Căliman-Sturdza, O. A. (2024) · Infectious diseases · doi:10.5772/intechopen.114918 · Cited by 5
Thompson, M. M., & Hassoun, A. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1300318 · Cited by 5
“[7] confirmed that a doubleb-lactam regimen (ampicillin plus ceftriaxone) was as effective as ampicillin plus gentamicin, in terms of treatment failure (1% vs 2%; p1⁄4 0.”
Background
Metadata
- Authors
- Fernández-Hidalgo, N., Almirante, B., Gavaldà, J., Gurgui, M., Peña, C., de Alarcón, A., Ruiz, J., Vilacosta, I., Montejo, M., Vallejo, N., López-Medrano, F., Plata, A., López, J., Hidalgo-Tenorio, C., Gálvez, J., Sáez, C., Lomas, J. M., Falcone, M., de la Torre, J., Martínez-Lacasa, X., & Pahissa, A.
- Affiliations
- Vall d'Hebron Hospital Universitari (ES)
- Bellvitge University Hospital (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Hospital Clínico San Carlos (ES)
- Hospital de Cruces (ES)
- Hospital Clínico Universitario de Valladolid (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Hospital Universitario de La Princesa (ES)
- Hospital Juan Ramón Jiménez (ES)
- Policlinico Umberto I (IT)
- University Hospital Mútua de Terrassa (ES)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-07
- Volume
- 56
- Issue
- 9
- Pages
- 1261-1268
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2137285136
- Semantic Scholar
- 9646599067b0e52124c95b08e69a38b3bd9e8a91
- Cited by
- 311
- References
- 22
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 25 · 2023: 23 · 2022: 16 · 2021: 19 · 2020: 26 · 2019: 35 · 2018: 21 · 2017: 21 · 2016: 23 · 2015: 26 · 2014: 16 · 2013: 19
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- Enterococcus faecalis, infective endocarditis, ampicillin, ceftriaxone, gentamicin, combination antibiotic therapy, aminoglycoside resistance, renal failure, treatment failure, relapse, mortality, adverse drug reactions
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Ampicillin, Anti-Bacterial Agents, Ceftriaxone, Drug Therapy, Combination, Endocarditis, Female, Gentamicins, Hospitals, Humans, Italy, Male, Middle Aged, Spain, Enterococcus faecalis, Cohort Studies, Treatment Outcome, Gram-Positive Bacterial Infections, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.